In the context of precision medicine, disease treatment requires individualized strategies
based on the underlying molecular characteristics to overcome therapeutic challenges …

Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger and a key
molecule in many important signaling cascades in the body and brain, including …

The successful development of amyloid-based biomarkers and tests for Alzheimer's disease
(AD) represents an important milestone in AD diagnosis. However, two major limitations …

Nonalcoholic steatohepatitis (NASH) is a major cause of liver‐related morbidity and mortality
worldwide. Liver fibrosis stage, a key component of NASH, has been linked to the risk of …

Background and Aims A reduction in hepatic venous pressure gradient (HVPG) is the most
accurate marker for assessing the severity of portal hypertension and the effectiveness of …

Cognitive impairment involves complex interactions between multiple pathways and
mechanisms, one of which being cardiac disorders. Atrial cardiopathy (AC) is a structural …

Background/Aims To explore the imaging changes and related risk factors of heart failure
(HF) patients with cognitive impairment (CI). Methods A literature search was systematically …

Background and objective Systemic autoinflammatory diseases (SAIDs) are characterized
by widespread inflammation, but for most of them there is a lack of specific biomarkers for …

Purpose: Neurodegenerative disorders are a global health burden with costly and invasive
diagnoses relying on brain imaging technology or CSF-based biomarkers. Therefore …

Alzheimer's disease (AD) stands as the prevalent progressive neurodegenerative disease,
precipitating cognitive impairment and even memory loss. Amyloid biomarkers have been …